ARCTis™ Human Tumor CryoKit Starter
ARCTis™ - Always Ready Cryo Tissues Convenient one-stop solution for testing compounds on 3D tumor cell cultures, cryopreserved in our well-known Akura™ 96 Plate. Thaw the plates at your convenience and let the cells recover for 3-5 days from the cryopreservation. All steps from thawing to endpoint analysis are done in the same Akura™ 96 Plate. Each plate is delivered with 30 ml thawing medium for ease of mind.
The supplier does not provide quotations for this product through SelectScience. You can search for similar products in our Product Directory.
The ARCTis™ Oncology portfolio enables the testing of compounds on plate formats without the issues deriving from shipping "freshly made" tumor spheroids (co-aligning of production and consumption, delivery delays through logistics or import/export concerns.) ARCTis™ Oncology plates allow you start testing compounds each time with the same start point for your tumor spheroids at your convenience. The allow for testing up to 9-11 days depending on the cell line doubling rate. The specially formulated thawing medium helps the cells to recover in a short period of time (3-5 days) and then are assay-ready. Based on the Akura™ 96 Spheroid Microplate medium exchange without loss of spheroids for ease of mind.
The ARCTis™ Starter Pack elements are as follows:
- 6 x ARCTis™ plates – 2 plates for each of three different tumor cell lines: HCT116 (AT-NB00-0T0-001 HCT116), A549 (AT-NB00-0T0-001 A549) and T-47D (AT-NB00-0T0-001 T-47D)
- 6 x 30ml Tumor Reaggregation Medium (CS-07-112-04)
- 4 x 125ml Tumor Maintenance Medium (CS-07-112-03)
- 1 x Tilting stand (CS-AG11)
New microplate platform with cryopreserved 3D tumor spheroids
Monotypic cancer models based on human tumor cell lines provide a simplified representation of specific cancer types, facilitating focused research and drug development efforts. InSphero presents ARCTis™, or Always Ready Cryo Tissues, using in-plate frozen cell solutions comprising various human tumor cell lines, facilitating a temporal disconnect between the production of 3D cell cultures and their application in experiments. This approach involves producing larger lot sizes, reducing production costs, and ensuring immediate product availability with shorter order lead times. ARCTis serves as a novel tool for early cancer research, offering monotypic cancer models based on human tumor cell lines.
